Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2000
03/21/2000US6039557 Apparatus for making gas-filled vesicles of optimal size
03/21/2000CA2148801C Restrained multifunctional reagent for surface modification
03/16/2000WO2000014118A1 Ozf protein-specific monoclonal antibodies and their diagnostic therapeutic uses
03/16/2000WO2000014019A1 A medical active water, manufacture and use thereof
03/16/2000WO2000013712A2 Methods and compositions for the prevention or treatment of cancer
03/16/2000WO2000013710A2 Hydrogel compositions for the controlled release administration of growth factors
03/16/2000WO2000013692A1 Ophthalmic compositions and process of using
03/16/2000WO2000013689A1 Methods and compositions for increasing intestinal absorption of fats
03/16/2000WO2000013687A2 Sustained release ranolazine formulations
03/16/2000WO2000013686A2 Sustained release ranolazine formulations
03/16/2000WO2000013677A1 Nanogel networks and biological agent composition thereof
03/16/2000WO2000013674A1 Dosage form comprising therapeutic formulation
03/16/2000WO2000013672A1 New solid dose form of nanoparticulate naproxen
03/16/2000WO2000013671A1 Immediate release tablet
03/16/2000WO2000013667A1 Lipstatin derivative-soluble fiber tablets
03/16/2000WO2000013665A1 Controlled release drug delivery
03/16/2000WO2000013664A1 Drug preparations for treating sexual dysfunction
03/16/2000WO2000013663A1 Dosage form comprising liquid formulation
03/16/2000WO2000013660A1 Lipid extract of the skeletonema algae
03/16/2000WO2000002582A3 Treatment of celiac disease with interleukin-15 antagonists
03/16/2000WO1999064047A9 Novel antiviral compounds
03/16/2000WO1999063932A9 Multibinding agents that modulate the 5-ht transporter
03/16/2000WO1999063929A9 Multibinding inhibitors of microsomal triglyceride transferase protein
03/16/2000WO1999059643A3 Liposomal delivery complex
03/16/2000WO1999058570A3 Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis
03/16/2000WO1999057151A3 FAP α-SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY
03/16/2000DE19841209A1 Slow-release caffeine tablets produced by direct compression of caffeine-containing plant materials or extracts
03/16/2000CA2342963A1 Ozf protein-specific monoclonal antibodies and their diagnostic therapeutic uses
03/16/2000CA2342800A1 Nanogel networks and biological agent composition thereof
03/16/2000CA2342769A1 Drug preparations for treating sexual dysfunction
03/16/2000CA2342625A1 Lipstatin derivative-soluble fiber tablets
03/16/2000CA2341752A1 Methods and compositions for the prevention or treatment of cancer
03/16/2000CA2308472A1 Ophthalmic compositions and process of using
03/15/2000EP0985732A2 Trimeric chimera protein and collagen matrix containing chimera protein
03/15/2000EP0985412A2 Cyclosporin compositions
03/15/2000EP0985411A1 Sterol esters in tableted solid dosage forms
03/15/2000EP0984788A1 Pharmaceutical compostions of peptides having low solubility in physiological medium
03/15/2000EP0984783A1 Anthelmintic compositions
03/15/2000EP0984774A1 Gastroretentive controlled release microspheres for improved drug delivery
03/15/2000EP0984773A1 Pharmaceutical formulation of omeprazole
03/15/2000EP0984771A1 Stabilized gas-supersaturated emulsions and suspensions
03/15/2000EP0814780A4 Diltiazem controlled release formulation
03/15/2000EP0806943B1 Valaciclovir tablets containing colloidal silicon dioxide
03/15/2000EP0729756B1 Granular preparation
03/15/2000EP0689425A4 Wound hydrating gel with novel preservative system and low cytotoxicity
03/15/2000EP0667767B1 Method for the preparation of creams
03/15/2000EP0643584B1 Delivery of a cytotoxic compound to a cancer cell using a pathway of plasminogen activator material
03/15/2000EP0633787B1 Use of ibuprofen-beta-cyclodextrin complex for oral consumption
03/15/2000EP0624098B1 Process of conjugation of antiviral nucleosides with lactosaminated human albumin
03/15/2000EP0567566B1 Methods for treating tumor necrosis factor mediated diseases
03/15/2000EP0549702B1 Use of recombinant colony stimulating factor-1
03/15/2000CN1247197A Application of copolymer including N-vinyl pyrrolidone and vinyl acetate
03/15/2000CN1247092A Activated medical water and its preparing process and usage
03/15/2000CN1247078A Process for preparing medical particles Qingkailing by wrapping chololic acid and animal extract with cyclodextrin
03/15/2000CN1247060A Novel medicinal compsns. containing cyclosporin
03/15/2000CN1050285C Method for prepn. of pressurised aerosol compositions
03/15/2000CN1050283C Gel-type cosmetic composite
03/14/2000US6037481 Process for stabilizing levogyre ascorbic acid (LAA), a stable aqueous LAA composition, a process for preparing a stable topical solution, an emulsion, a vitamin product, and a method for cosmetic, pharmaceutical or nutritional treatment
03/14/2000US6037467 Methods for preparing carbohydrate-containing hydrophilic polymers
03/14/2000US6037452 Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
03/14/2000US6037369 Administering caffeic acid or b-(3,4-dihydroxyphenyl)-lactic acid conjugate
03/14/2000US6037329 Compositions containing nucleic acids and ligands for therapeutic treatment
03/14/2000US6037323 Peptides and peptide analogues that mimic the structural and pharmacological properties of human apoa-i; treating disorders associated with dyslipoproteinemia, including hypercholesterolemia, cardiovascular disease, atherosclerosis,
03/14/2000US6036978 Antiinflammatory agents for gastrointestinal disorders
03/14/2000US6036977 Drug preparations for treating sexual dysfunction
03/14/2000US6036975 Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof
03/14/2000US6036973 Therapy for neurological diseases
03/14/2000US6036955 Antitumor agents
03/14/2000US6036948 Polyaspartamide derivatives as adsordents for bile acids, polyaspartamide derivatives loaded with bile acids and process for their preparation and their use as pharmaceuticals
03/14/2000US6036940 Compositions and methods relating to the production, isolation, and modification of gas vesicles
03/14/2000CA2013188C Preservative system for ophthalmic formulations
03/09/2000WO2000012706A1 Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
03/09/2000WO2000012619A1 Dextran-maleic acid monoesters and hydrogels based thereon
03/09/2000WO2000012588A1 Urethane(meth)acrylates containing siloxane groups and able to undergo free-radical polymerisation
03/09/2000WO2000012556A1 High-affinity antibodies
03/09/2000WO2000012554A1 Method for marked chemokine synthesis, marked chemokine and analysis kit
03/09/2000WO2000012538A1 Triple helix coil template having a biologically active ligand
03/09/2000WO2000012147A1 Drug delivery device for stent
03/09/2000WO2000012137A1 Preserved cyclodextrin-containing compositions
03/09/2000WO2000012136A1 Powdery pernasal compositions
03/09/2000WO2000012135A1 Medicinal compositions with relieved bitterness, etc.
03/09/2000WO2000012125A1 Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
03/09/2000WO2000012124A1 Oral vaccine compositions
03/09/2000WO2000012107A1 Composition containing pyrrolizidine-alkaloid-free petasites
03/09/2000WO2000012100A1 Inherently antimicrobial quaternary amine hydrogel wound dressings
03/09/2000WO2000012096A1 Anti-inflammatory ointments
03/09/2000WO2000012070A1 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
03/09/2000WO2000012068A1 Method for producing solid dosing forms
03/09/2000WO2000012066A1 Alginate capsules for use in the treatment of brain tumour
03/09/2000WO2000012065A1 Microparticulate composition
03/09/2000WO2000012064A1 Omeprazole formulation
03/09/2000WO2000012061A1 Synthetic tear fluid
03/09/2000WO2000012060A1 Electrically controlled transport of charged penetrants across barriers
03/09/2000WO2000012043A1 Improved stability for injection solutions
03/09/2000WO2000011946A2 Prolonged storage of red blood cells
03/09/2000WO1999067291A3 Site specific protein modification by mutagenesis
03/09/2000DE19839515A1 Association of active agent with colloidal polymer, preferably new polymeric branched polyol ester, useful for controlled transmucosal administration of e.g. peptide, DNA construct or vaccine
03/09/2000DE19807731A1 Verfahren zur Herstellung eines Träger- und Speichermaterials für Pflanzen und deren Wirkstoffe, Herstellung von Flüssigkeiten daraus und Verwendung als kosmetisches, therapeutisches und Reinigungsmittel A method for producing a carrier and storage material for plants and their active ingredients, preparation of liquids therefrom and use as a cosmetic, therapeutic and detergent
03/09/2000CA2731995A1 Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
03/09/2000CA2514899A1 Method of modulating memory effector t-cells and compositions
1 ... 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 ... 1712